



## ***Anti-human LDL receptor Antibody Monoclonal, LR-LL8H6***

### **ORDERING INFORMATION**

**Catalog Number:** BML028

**Lot Number:**

**Size:** 50 µg

**Formulation:** 0.2 µm filtered PBS solution

**Storage:** -80°C

**Specificity:** human LDL receptor

**Immunogen:** synthetic peptide

**Ig Type:** IgG2a

**Application:** Western blot

Flowcytometry

Immunohistochemistry

### ***Preparation***

Produced in mice immunized with synthetic peptides, aa158-175 (WPARCGARPSPQPGRGPC), which is corresponding to the ligand binding domain linker site of human low-density lipoprotein (LDL) receptor (LDL-R). LDL-R specific IgG was purified from mouse ascites fluid with a protein A-Sepharose.

### ***Formulation***

0.2 µm filtered PBS solution

### ***Storage***

IgG in PBS solution are stable for twelve months from the date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles.

### ***Specificity***

This antibody has been selected for its ability to bind for human LDL-R expressed in CHO cells (*ldl-A7*). No cross-reactivity with human VLDL receptor and apoER2 receptor was confirmed (see ref. 1).

### ***Additional Applications***

**Western Blot** - This antibody can be used at 1.0 µg/mL for western blot analysis (1).

**Flow cytometry** - This antibody can be used as a 1st antibody for immunohistochemistry. Please see the references (2) and (3) for details.

**Immunohistochemistry** - This antibody can be used for immunohistochemistry (4).

**Optimal dilutions should be determined by each laboratory for each application.**

### ***References***

- (1) Kosaka et al., Evidence of macrophage form cell formation by very low-density lipoprotein receptor: Interferon-γ inhibition of very low-density lipoprotein receptor expression and form cell formation in macrophages. *Circulation*, 2001;103:1142-1147.
- (2) Takahashi et al., A novel mutation in exon 2 of the low-density lipoprotein-receptor gene in a patient with homozygous familial hypercholesterolemia. *Clin Genet*, 2001;59:290-292.
- (3) Iwasaki et al., The important role for BVLDLs binding at the forth cysteine of first ligand-binding domain in the low-density lipoprotein receptor. *J Hum Genet*, 2004;49:622-628.
- (4) Motoi et al., Apolipoprotein E receptor 2 is involved in neuritic plaque formation in APP sw mice. *Neurosci Lett*, 2004;368:144-147

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

**BML, Inc.**

1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan  
TEL +81-49-232-0440/FAX +81-49-232-5480